Immix Biopharma Investor Presentation Deck

N-GENIUS Technology Platform - NXC-201 rapidly eliminates diseased AL Amyloidosis plasma cells and exits within 30 days (2/2) HB10101 cell/m L Blood HB10101/mL Blood 30 days 2×105. 1.5x105- 1x105- 5x104- 1 0 dFLC (mg/L) 0 20 40 60 Days to CART infusion 80 600 400 · 200 0 dFLC (mg/L) ●●● IMMIX S BIOPHARMA *dFLC (=involved FLC-un involved FLC) Source: NXC-201 (formerly known as HBI0101). Nexcella ASGCT Presentation Los Angeles 2023. E. Lebel et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI10101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023. 11

View entire presentation